Literature DB >> 59817

Sequence homology between Moloney murine sarcoma virus and Moloney leukemia virus RNA.

M Bondurant, C M Stoltzfus, W M Mitchell.   

Abstract

The Moloney murine sarcoma-leukemia virus [M-MSV (MuLV)], propagated at high multiplicity of infection (MOI), was demonstrated previously to contain a native genome mass of 4 X 10(6) daltons as contrasted to a mass of 7 X 10(6) daltons for Moloney murine leukemia virus (M-MuLV). The 4 X 10(6)-dalton classof RNA from M-MSV (MuLV) was examined for base sequence homology with DNA complementary to the 7 X 10(6)-dalton M-MuLV RNA genome. Approximately 86% of the M-MSV (MuLV) was protected from RNase digestion by hybridization, whereas 95% of M-MuLV was protected under identical conditions. These results indicate that the small RNA class of high-MOI M-MSV (MuLV) contains little (perhaps 10%) genetic information not present in M-MuLV. Virtually all of the 1.8 X 10(6)-dalton subunits of M-MSV (MuLV) RNA contained regions of poly(A) since 94% of the RNA bound to oligo(dT) cellulose in 0.5 M KCl. This suggests that the formation of the 1.8 X 10(6)-dalton subunits occurs before their packaging into virions and does not result from hydrolysis of intact 3.5 X 10(6)-dalton subunits by a virion-associated nuclease.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 59817      PMCID: PMC354834     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  14 in total

1.  Base sequence differences between the RNA components of Harvey sarcoma virus.

Authors:  J Maisel; E M Scolnick; P Duesberg
Journal:  J Virol       Date:  1975-09       Impact factor: 5.103

2.  Activation of the murine sarcoma virus genome after infection with the murine leukemia virus as determined by cell agglutination.

Authors:  S Salzberg; M Green
Journal:  J Virol       Date:  1974-05       Impact factor: 5.103

3.  Strandedness and complementarity of DNA from long-term RNA-dependent DNA polymerase reactions of Soehner-Dmochowski murine sarcoma virus.

Authors:  J L East; J E Knesek; P T Allen; L Dmochowski
Journal:  J Virol       Date:  1973-11       Impact factor: 5.103

4.  Correlation between murine sarcoma virus buoyant density, infectivity, and viral RNA electrophoretic mobility.

Authors:  J S Manning; F L Schaffer; M E Soergel
Journal:  Virology       Date:  1972-09       Impact factor: 3.616

5.  Viral RNA of murine sarcoma virus produced by a hamster-mouse somatic cell hybrid.

Authors:  N Tsuchida; C Long; M Hatanaka
Journal:  Virology       Date:  1974-07       Impact factor: 3.616

6.  Ribonucleic acid components of murine sarcoma and leukemia viruses.

Authors:  J Maisel; V Klement; M M Lai; W Ostertag; P Duesberg
Journal:  Proc Natl Acad Sci U S A       Date:  1973-12       Impact factor: 11.205

7.  Infectivity and RNA patterns as functions of high- and low-dilution passage of murine sarcoma-leukemia virus: evidence for autointerference within an oncornavirus population.

Authors:  M C Bondurant; A J Hackett; F L Schaffer
Journal:  J Virol       Date:  1973-05       Impact factor: 5.103

8.  Evidence for crossing-over between avian tumor viruses based on analysis of viral RNAs.

Authors:  K Beemon; P Duesberg; P Vogt
Journal:  Proc Natl Acad Sci U S A       Date:  1974-10       Impact factor: 11.205

9.  Lack of sequence homology among RNAs of avian leukosis-sarcoma viruses, reticuloendotheliosis viruses, and chicken endogenous RNA-directed DNA polymerase activity.

Authors:  C Y Kang; H M Temin
Journal:  J Virol       Date:  1973-12       Impact factor: 5.103

10.  The homopolyadenylate and adjacent nucleotides at the 3'-terminus of 30-40s RNA subunits in the genome of murine sarcoma-leukemia virus.

Authors:  H M Rho; M Green
Journal:  Proc Natl Acad Sci U S A       Date:  1974-06       Impact factor: 11.205

View more
  1 in total

1.  "sarc" sequence transcription in Moloney sarcoma virus-transformed nonproducer cell lines.

Authors:  M Bondurant; R Ramabhadran; M Green; W S Wold
Journal:  J Virol       Date:  1979-01       Impact factor: 5.103

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.